Literature DB >> 23599674

Pharmaceutical approval update.

Marvin M Goldenberg.   

Abstract

Cabozantinib (Cometriq) for metastatic medullary thyroid cancer; ponatinib (Iclusig) for two forms of leukemia; and raxibacumab for inhalational anthrax.

Entities:  

Year:  2013        PMID： 23599674      PMCID： PMC3628176     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  5 in total

1.  Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer.

Authors:  Ling-Chuan Guo; Wei-Dong Zhu; Xiang-Yuan Ma; Hao Ni; En-Jian Zhong; Yang W Shao; Jie Yu; Dong-Mei Gu; Shun-Dong Ji; Hao-Dong Xu; Cheng Ji; Jin-Ming Yang; Yi Zhang
Journal:  Cancer Biol Ther       Date:  2018-09-25       Impact factor: 4.742

Review 2.  Cabozantinib for progressive metastatic medullary thyroid cancer: a review.

Authors:  Joshua R Colombo; Richard O Wein
Journal:  Ther Clin Risk Manag       Date:  2014-05-28       Impact factor: 2.423

Review 3.  New therapies for dedifferentiated papillary thyroid cancer.

Authors:  Poupak Fallahi; Valeria Mazzi; Roberto Vita; Silvia Martina Ferrari; Gabriele Materazzi; David Galleri; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2015-03-17       Impact factor: 5.923

Review 4.  Molecular Targeted Therapies of Aggressive Thyroid Cancer.

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ugo Politti; Gabriele Materazzi; Enke Baldini; Salvatore Ulisse; Paolo Miccoli; Alessandro Antonelli
Journal:  Front Endocrinol (Lausanne)       Date:  2015-11-20       Impact factor: 5.555

5.  Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice.

Authors:  Avanish K Varshney; Xiaobo Wang; Jorge L Aguilar; Matthew D Scharff; Bettina C Fries
Journal:  MBio       Date:  2014-06-10       Impact factor: 7.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.